Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer.

Giulia SiravegnaAndrea Sartore-BianchiRebecca J NagyKanwal RaghavJustin I Odegaard Richard B LanmanLivio TrusolinoSilvia MarsoniSalvatore SienaAlberto Bardelli

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

cfDNA is a viable alternative to tissue-based genotyping in the metastatic setting. The cfDNA platform utilized correctly identified 28 of 29 (96.6%) of pretreatment samples as ERBB2-amplified and predicted benefit from HER2-targeted therapy. In this study, an observed pCN of 2.4 and an adjusted pCN of 25.82 copies of ERBB2 are proposed to select patients who will benefit from HER2-targeted therapy.

Keyphrases

copy number
metastatic colorectal cancer
mitochondrial dna
tyrosine kinase
genome wide
high throughput
small cell lung cancer
dna methylation
gene expression